

This is not March 2016 in replay

In our previous research publications, we explained that improving the FCY liquidity within the banking system is a key objective whether the Central Bank of Egypt (CBE) will let the EGP float freely or will manage the EGP float (see 'Why Devaluation is Not Going to Solve it All' published on October 18). We also noted that a full EGP float is preferred from a macroeconomic perspective, but a managed float looks to be more politically appropriate. We reiterate that exchange rate flexibility is part and parcel of the International Monetary Fund (IMF) reform programme. That is why we expect more frequent exchange rate adjustments in the coming weeks, even under a managed float scenario.

Hence, we believe that the CBE's strategy will include a sharp and frequent, albeit less-than-expected, exchange rate movements, in addition to more-than-expected and frequent FCY injections.

Devaluation should be penciled in for November

Previously communicated dates by government officials show that devaluation should be penciled in for November. Finance Minister, Amr El Garhy, noted that the Eurobond issuance should happen after mid-November. In addition, the MPC meets to decide on interest rates on November 17, which we estimate would be the time for a significant rate hike (c.200bps), in a bet to raise the attractiveness of the EGP as an investment vehicle and attract fixed income portfolio inflows from international investors. These dates tell us that a devaluation in November is, now, very probable.


Keep an eye on the 3-month non-deliverable forwards (NDFs) exchange rate, not just the parallel market exchange rate

Monitoring the 3M NDFs provides a less-speculative picture of the real market value of the EGP/USD exchange rate. More importantly, previous rounds of the EGP devaluation did show that the 3M NDF exchange rate can be used as a strong indicator for the magnitude of the CBE's next official rate adjustment (Figure 1). For example, the 3-month NDF rate averaged EGP8.80 per USD in February 2016, just before the exchange rate went officially to EGP8.88 versus the USD in March 2016. The 3-month NDFs exchange rate averaged EGP11.00 per USD in September 2016 and EGP12.05 per USD as of October 24, with the one-month moving average recording EGP11.80 per USD. The aforementioned readings suggest that the next exchange rate move could be somewhere between EGP11.00 - 12.00 versus USD. In that context, we note that the reported 'parallel market' rates are quite useful in defining the EGP/USD trend, rather than the exchange rate value, due to unrealistic speculation and the high risk premium.

NIR build-up and FX intervention limitation represent the other side of the coin

For a managed float scenario to be successful, an exchange rate readjustment should be frequent and accompanied by an adequate FCY injection to support the new exchange rate. Generally, the IMF supports that the NIR would secure an import coverage ratio of 4.5-5.0 months. Such a target, we believe, could act as the NIR floor set by the fund, which points to an NIR floor of USD 21.0-23.0 billion. Accordingly, we believe that the CBE's ability to intervene in the FX market will be limited, but not zero.

Figure 1 | 3-month NDFs exchange rate is a better indicator to follow than parallel market exchange



Source: Bloomberg, Pharos Research

Mechanism: One large leap, followed by limited frequent injections to avoid NIR depletion

Assuming that Egypt has secured the USD6 billion required by the IMF in October, we estimate the CBE's NIR import coverage level at that point would hit 4.6 months of imports. Hence, together with the disbursement of the IMF facility's first tranche (USD 2.5 billion) and the international bond issuance (USD 2.5 - 3.0 billion), the CBE's FCY ammunition is well above the set floor for a few months until the official exchange rate policy would have gained better ground, leading to weaker speculative attacks. One important note is that we believe that FCY injection will walk hand-in-hand with more flexible movements in the exchange rate to ensure NIR preservation. The larger the EGP devaluation, the less CBE's FCY injections.

In brief, we believe that applying a flexible exchange rate regime, in addition to suppressing speculative attacks entail the implementation of the following measures altogether in a very narrow timeframe:

- (1) An initial sharp, but less than expected, EGP devaluation,
- (2) A more than expected FCY injection according to the above-mentioned mechanism,
- (3) A domestic interest rate rise of 200 basis points to raise local currency appeal, anchor inflation expectations and attract foreign fund inflows, and
- (4) Utilise the positive sentiment following the IMF loan approval and receiving the first tranche of the loan to stabilise the official exchange rate.

Finally, we reiterate that Egypt's external sector outlook remains 'negative,' meaning that the EGP will continue to weaken in FY2016/17, hence, "flexibility" on exchange rate movements will continue be required.



Sales and Trading

Mohamed Radwan
Head of Equities
+202 27393680
mohamed.radwan@pharosholding.com

Ahmed Raafat
Local Institutional Sales
+202 27393687
ahmed.raafat@pharosholding.com

Sherif Shebl
Regional Sales
+202 27393679
sherif.shebl@pharosholding.com

Ahmed Abutaleb
Foreign Sales
+202 27393684
ahmed.abutaleb@pharosholding.com

Seif Attia
High Net Worth
+202 27393682
seif.attia@pharosholding.com

Disclaimer

This Report is compiled and furnished solely for informative purposes to be considered by the intended recipients who have the knowledge to assess the information contained herein. Pharos Research ("Pharos") makes no representation or warranty, whether expressed or implied, as to the accuracy and/or completeness of the information contained herein or any other information that may be based on the data/ information enclosed. Furthermore, Pharos hereby disclaims any and all liabilities of any nature relating to or resulting from the use of the contents of this Report. This Report shall not be approached as an investment solicitation nor shall it be considered as legal or tax advice. Pharos highly recommends that those viewing this Report seek the advice of professional consultants. None of the materials provided in this Report may be used, reproduced or transmitted, in any form or by any means, electronic or mechanical, including recording or the use of any information storage and retrieval system, without written permission from Pharos.

This report was prepared, approved, published and distributed by Pharos Securities Brokerage company located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by LXM LLP USA, a U.S. registered broker dealer, on behalf of Pharos Securities Brokerage only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through LXM LLP USA.

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

Analyst Certification. Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Please bear in mind that (i) Pharos Securities Brokerage is the employer of the research analyst(s) responsible for the content of this report and (ii) research analysts preparing this report are resident outside the United States and are not associated persons of any US regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a US broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Important US Regulatory Disclosures on Subject Companies. This material was produced by Analysis Pharos Securities Brokerage solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by LXM LLP USA and elsewhere in the world by Pharos Securities Brokerage or an authorized affiliate of Pharos Securities Brokerage. This document does not constitute an offer of, or an invitation by or on behalf of Pharos Securities Brokerage or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Pharos Securities Brokerage or its Affiliates consider to be reliable. None of Pharos Securities Brokerage accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

LXM LLP USA assumes responsibility for the research reports content in regards to research distributed in the U.S. LXM LLP USA or its affiliates has not managed or co-managed a public offering of securities for the subject company in the past 12 months, has not received compensation for investment banking services from the subject company in the past 12 months, does not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next 3 months. LXM LLP USA has never owned any class of equity securities of the subject company. There are not any other actual, material conflicts of interest of LXM LLP USA at the time of the publication of this research report. As of the publication of this report LXM LLP USA, does not make a market in the subject securities.